Antonio Rueda-Domínguez

9PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsiesHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Feb 17, 2026
SEOM-TTCC clinical guideline for nasopharyngeal carcinoma (update 2025).

Antonio Rueda Domínguez, Beatriz Cirauqui, Almudena García Castaño

|Oct 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Martin Hutchings, Anna Sureda, Francesc Bosch

|Jul 17, 2025
Paving the way for ctDNA-guided trials in lung cancer: insights from the LIBELULE study.

Jose Carlos Benitez, Antonio Rueda-Domínguez

|Feb 13, 2025
Ketone Bodies Are Potential Prognostic Biomarkers in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results from the R2-GDP-GOTEL Trial.

Sara Fernández-Castillejo, Joan Badia, Luís de la Cruz-Merino

|Jul 14, 2023
Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade.

Javier Oliver, Juan Luis Onieva, María Garrido-Barros

|Jan 08, 2023
Prognostic Impact of Sarcopenia in Patients with Advanced Prostate Carcinoma: A Systematic Review.

Pedro de Pablos-Rodríguez, Tasmania Del Pino-Sedeño, Diego Infante-Ventura

Pageof 2

Frequent Collaborators

3 joint publications

Laura Gálvez-Carvajal

2 joint publications

Mariano Provencio-Pulla

2 joint publications

Josep Gumá

2 joint publications

José Carlos Benítez